CJC-1295 DAC (5mg)

CJC-1295 DAC 5mg, a long-acting GHRH analogue with extended half-life.(99%) Purity verified here on Australian soil at The University of Melbourne.

CJC-1295 with DAC (Drug Affinity Complex) is a long-acting growth hormone releasing hormone analogue. The DAC modification is a lysine residue linked to a reactive chemical group that enables covalent binding to serum albumin after administration, significantly extending the biological half-life compared to the non-DAC version.

This extended duration is achieved through reversible albumin binding, creating a circulating reservoir that releases active peptide over an extended period. Research has shown that the DAC modification extends the half-life from approximately 30 minutes (non-DAC) to several days, fundamentally changing the pharmacokinetic profile.

Studies have compared the pharmacodynamics of CJC-1295 DAC versus the non-DAC version, examining differences in GH release patterns. The DAC version produces more sustained GH elevation, while the non-DAC version produces pulsatile release more similar to natural physiological patterns.

Research has investigated the implications of continuous versus pulsatile GH stimulation on downstream effects including IGF-1 levels, body composition changes, and receptor desensitisation. These studies help characterise the different research applications for each variant.

Gen Ex Peptides supplies CJC-1295 DAC tested at an Australian university laboratory not generic overseas certificates. Each batch is verified for purity (99%) using HPLC and mass spectrometry.